D. Muchmore

D. Muchmore, V. Vint, Christopher W. Marx, 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effect of standard (self-directed) training versus intensive training for Lilly/Alkermes human insulin inhalation powder delivery system on patient-reported outcomes and patient evaluation of the system.

R. Hayes, D. Muchmore, M. Nakano, 2007, Diabetes technology & therapeutics.

Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine.

J. Rosenstock, R. Hayes, D. Muchmore, 2009, Diabetes technology & therapeutics.

Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 Diabetes

D. Klonoff, M. Penn, B. Bode, 2019, Diabetes Care.

Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes

J. Buse, J. Skyler, D. Muchmore, 2014, Diabetes, obesity & metabolism.

Counterregulatory control of intracellular hydrogen peroxide production by insulin and lipolytic hormones in isolated rat epididymal fat cells: a role of free fatty acids.

D. Muchmore, C. de Haën, S. Little, 1982, Biochemistry.

Inhaled micronized crystalline human insulin using a dry powder inhaler: dose‐response and time‐action profiles 1

L. Heinemann, K. Rave, L. Nosek, 2004, Diabetic medicine : a journal of the British Diabetic Association.

On the Mechanisms of Inhibition of Insulin Action by Small-Molecular-Weight Trypsin Inhibitors

R. Bergstrom, D. Muchmore, C. de Haën, 1982, Diabetes.

Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase

D. Muchmore, L. Morrow, D. Vaughn, 2013, Diabetes Care.

Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers.

D. Muchmore, L. Morrow, D. Vaughn, 2011, Diabetes technology & therapeutics.

Amylin concentrations and glucose control

G. Dailey, M. Fineman, D. Muchmore, 1992, The Lancet.

Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.

D. Muchmore, L. Morrow, D. Vaughn, 2012, Diabetes technology & therapeutics.

Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes

J. Rosenstock, S. Garg, B. Silverman, 2006, Diabetologia.

A dual mechanism of action of ocytocin in rat epididymal fat cells.

D. Muchmore, C. de Haën, S. Little, 1981, The Journal of biological chemistry.

Assessing Rates of Hypoglycemia as an End Point in Clinical Trials

L. Heinemann, W. Tamborlane, X. Wu, 2015, Diabetes Care.

Coverage of Prandial Insulin Requirements: An Elusive Goal.

L. Heinemann, D. Muchmore, 2017, Diabetes technology & therapeutics.

Benefits of Blinded Continuous Glucose Monitoring during a Randomized Clinical Trial

D. Muchmore, D. Vaughn, Melissa Sharp, 2011, Journal of diabetes science and technology.

Regarding: Insulin Infusion Set Failures.

D. Muchmore, 2022, Diabetes technology & therapeutics.

Feasibility study of a prototype extended‐wear insulin infusion set in adults with type 1 diabetes

D. Muchmore, S. Fourlanos, J. Joseph, 2022, Diabetes, obesity & metabolism.

Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusion.

D. Muchmore, D. Vaughn, 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Late-Breaking Clinical Trial Report

D. Muchmore, D. Vaughn, 2011 .

Reduced hypoglycaemia using liver‐targeted insulin in individuals with type 1 diabetes

D. Klonoff, S. Garg, M. Penn, 2022, Diabetes, obesity & metabolism.

Subcutaneous Insulin Administration: Sufficient Progress or Ongoing Need?

L. Heinemann, D. Muchmore, R. Pettis, 2018, Journal of diabetes science and technology.

Stimulation of Intracellular H2 02 Production in Rat Epididymal Adipocytes by Insulin, Insulin Fragments, and Other Hormones and Growth Factors with Insulin-Like Activities

C. D. Haën, D. Muchmore, S. Little, 1980 .

Accelerating and Improving the Consistency of Rapid-Acting Analog Insulin Absorption and Action for Both Subcutaneous Injection and Continuous Subcutaneous Infusion Using Recombinant Human Hyaluronidase

D. Muchmore, D. Vaughn, 2012, Journal of diabetes science and technology.

Estimating Dose Equivalence for New Routes of Drug Administration

J. Chien, D. Muchmore, G. Weerakkody, 2004, Journal of biopharmaceutical statistics.

Accelerated Insulin Pharmacokinetics and Improved Postprandial Glycemic Control in Patients With Type 1 Diabetes After Coadministration of Prandial Insulins With Hyaluronidase

D. Muchmore, L. Morrow, D. Vaughn, 2011, Diabetes Care.

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

B. Sugarman, S. Dychter, D. Muchmore, 2015, The AAPS Journal.

Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase.

B. Sugarman, D. Muchmore, D. Vaughn, 2009, Diabetes technology & therapeutics.

Recombinant Human PH20: Baseline Analysis of the Reactive Antibody Prevalence in the General Population Using Healthy Subjects

B. Sugarman, D. Muchmore, S. Rosengren, 2018, BioDrugs.

Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects.

D. Muchmore, 2000, The oncologist.

Inhaled insulin for controlling blood glucose in patients with diabetes

C. J. Barnes, B. Campaigne, B. Silverman, 2007, Vascular health and risk management.

CHAPTER 73 – Estrogen Analogues: Selective Estrogen Receptor Modulators and Phytoestrogens

E. Siris, R. Prince, D. Muchmore, 2008 .

Selective Estrogen Receptor Modulators (SERMs)

E. Siris, D. Muchmore, 2001 .

Hypoglycemia evaluation and reporting in diabetes: Importance for the development of new therapies

D. Klonoff, B. Frier, D. Muchmore, 2017, Diabetes/metabolism research and reviews.

Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women

Robert Marcus, R. Marcus, A. Parfitt, 2003, Osteoporosis International.

Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro.

L. Heinemann, K. Rave, L. Nosek, 2005, Diabetes care.

AIR Inhaled Insulin in Subjects With Chronic Obstructive Pulmonary Disease

L. Heinemann, K. Rave, F. Tibaldi, 2007, Diabetes Care.

Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients.

M. Dowsett, F. Cohen, P. Veronesi, 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

The End Point is Just the Beginning

D. Muchmore, 2011, Journal of diabetes science and technology.

Self-monitoring of blood glucose in overweight type 2 diabetic patients

D. Muchmore, J. Springer, M. Miller, 1994, Acta Diabetologica.

Pump Users Clamor for Faster Insulin: Is Fast-Acting Insulin Aspart Ready for Them?

D. Muchmore, 2018, Journal of diabetes science and technology.

AIR insulin capsules of different dose strengths may be combined to yield equivalent pharmacokinetics and glucodynamics.

L. Heinemann, K. Rave, B. Silverman, 2009, Diabetes technology & therapeutics.

Does availability of AIR insulin increase insulin use and improve glycemic control in patients with type 2 diabetes?

N. Freemantle, R. Bergenstal, R. Hayes, 2009, Diabetes technology & therapeutics.

Progressive Acceleration of Insulin Exposure Over 7 Days of Infusion Set Wear

T. Bailey, K. Oberg, D. Muchmore, 2022, Diabetes technology & therapeutics.